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Background: Malignant astrocytomas are the most common primary brain tumors and one of the most lethal
among human cancers despite optimal treatment. Therefore, the characterization of molecular alterations
underlying the aggressive behavior of these tumors and the identification of new markers are thus an important
step towards a better patient stratification and management.
Methods and results: VRK1 and VRK2 (Vaccinia-related kinase-1, -2) expression, as well as proliferation markers,
were determined in a tissue microarray containing 105 primary astrocytoma biopsies. Kaplan Meier and Cox models
were used to find clinical and/or molecular parameters related to overall survival. The effects of VRK protein levels
on proliferation were determined in astrocytoma cell lines. High levels of both protein kinases, VRK1 or VRK2,
correlated with proliferation markers, p63 or ki67. There was no correlation with p53, reflecting the disruption of the
VRK-p53-DRAM autoregulatory loop as a consequence of p53 mutations. High VRK2 protein levels identified a
subgroup of astrocytomas that had a significant improvement in survival. The potential effect of VRK2 was studied
by analyzing the growth characteristics of astrocytoma cell lines with different EGFR/VRK2 protein ratios.
Conclusion: High levels of VRK2 resulted in a lower growth rate suggesting these cells are more indolent.
In high-grade astrocytomas, VRK2 expression constitutes a good prognostic marker for patient survival.
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Malignant astrocytomas represent 70% of adult malig-
nant primary brain tumors and are one of the most dev-
astating cancers [1]. Astrocytomas are classified in four
grades on the basis of histological and clinical criteria
established [2]. Grade I astrocytomas occur more in chil-
dren, are curable by surgery and might represent a separate
disease from the astrocytomas of other grades [3], however,
virtually all high-grade astrocytomas eventually progress
and locally relapse regardless of improved diagnosis and
multi-modality treatment [4,5]. For most brain tumors
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astrocytomas are related to their genetic and chromo-
somal alterations. Malignant astrocytomas have well
identified molecular characteristics and a basic pattern
of common genetic alterations, which include PTEN,
TP53, IDH1/2 and p16 mutations, and EGFR, CDK4 and
MDM2 amplification [1,6].
The human vaccinia-related kinase (VRK) family of
serine-threonine kinases is composed of three members,
of which only two (VRK1 and VRK2) are catalytically active
kinases [7]. Recently, the VRK family has been implicated
in different types of neurologic diseases. VRK1 has been
associated with pontocerebellar hypoplasia with ataxias and
muscular atrophy symptoms [8,9], and VRK2 has been
linked to schizophrenia [10-12] and epilepsy [13]. But most
of VRK proteins functional roles have been identified in the
context of cancer biology [14]. Nuclear VRK1 regulates cell
cycle progression by controlling the exit from G0 phase,ioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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transcription factors such as p53 [16-18] c-Jun [19], ATF2
[20] and CREB [21], as well as histone H3 facilitating
chromatin compaction [22]. VRK1 also regulates cellular
responses to radiation mediated by p53 or 53BP1 [23]. In
addition, VRK1 and p53 form an autoregulatory loop where
p53 downregulates VRK1 by the autophagic pathway
[24,25]. VRK1 is thus a new important regulator of cell
proliferation [14], and high VRK1 protein levels have been
associated with the proliferation phenotype in head and
neck squamous cell carcinomas [26] and lung cancer [27].
VRK2 has two isoforms, VRK2A and VRK2B. The full-
length protein (known as VRK2A or VRK2) is located in
the cytosol anchored to endoplasmic reticulum and
mitochondrial membranes [28], while the shorter VRK2B is
free and present in cytosol and nucleus [28]. VRK2A effects
are mediated mostly by its interactions with scaffold
proteins that affect cellular signaling. The interaction of
VRK2A with JIP1 is able to partially inhibit the stress
response to hypoxia [29] or to the interleukin1β [30].
VRK2 also interacts with the KSR1 scaffold protein and
downregulates the signal originated in the EGF/Ras/Raf/
Mek/Erk pathway [31,32].
In this work we have tested the potential value of
VRK1 and VRK2 protein levels as prognostic markers in
low and high-grade astrocytomas, based on the observation
that these proteins have an effect on proteins that are
known to be affected in the pathogenesis of astrocyto-
mas, such as p53, or EGFR signaling, as well as on other
regulators of cell cycle progression.
Methods
Patients and samples
The study was performed with 105 adult patients diag-
nosed with primary astrocytoma grades II to IV. The cases
included 25 diffuse low-grade astrocytomas (grade II), 20
anaplastic astrocytomas (grade III) and 60 glioblastomasH&E PNegative VRK1 
Low-grade 
Astrocytomas
High-grade 
Astrocytomas
Figure 1 Illustration of tumor cases representing images of low and h
(H&E) staining, as well as negative and positive expression of VRK1 and VRK(grade IV) according to WHO criteria [2]. The character-
istics of the patients are summarized in Additional file 1:
Tables S1 and Additional file 2: Table S2. All samples were
obtained with informed consent for publication of patient
data and protocols approved by the ethics and scientific
committees of the Hospital Universitario de Salamanca
and national guidelines for samples of human origin.Tissue microarray and immunohistochemistry
Formalin-fixed paraffin-embedded tissue samples were
used to prepare a tissue microarray (TMA) made with a
Tissue Arrayer device (Beecher Instrument, MD). Three
1-mm-diameter cylinders of each tumor were included
to ensure quality, reproducibility and homogenous staining
of the slides. Thus, three TMA blocks were constructed,
each containing the 105 astrocytoma tumors along with
controls of different tissues. Immunohistochemical staining
was performed on these sections using p53 (clone DO-7,
Novocastra), p63 (clone 4A4, Dako), ki-67 (clone MIB-1,
Dako), VRK1 [33] and VRK2 [28] antibodies. Immunohisto-
chemical staining was evaluated semiquantitatively by a
blinded pathologist to clinical or molecular information as
follows: ki-67 expression was considered positive when >5%
of tumor cells showed immunoreactivity; p53, p63, VRK1
and VRK2 expression were scored positive when >50% of
tumor cells showed intense staining.DNA extraction and mutation analysis of p53 and
IDH1/2 genes
DNA from frozen tumor specimens was extracted by
standard phenol/chloroform procedure. All coding exons
of p53, exon 4 of IDH1 and exon 4 of IDH2 genes were
screened for mutations by PCR amplification and direct
sequencing analysis using an ABI Prism 3100 Genetic
Analyzer (Applied Biosystems). Primer sequences are
listed in Additional file 3: Table S3.ositive VRK1 Positive VRK2 Negative VRK2 
igh-grade astrocytomas. The images show hematoxylin and eosin
2 proteins. Images were taken with a magnification of × 400.
Table 1 Expression of markers in low and high-grade
astrocytomas, VRK1 expression
VRK1 (nuclear staining) P value
Tumor Negative Positive Total
Low-Grade 15 (62.5%) 9 (37.5%) 24 (100%) P = 0.146
High-Grade 36 (45.6%) 43 (54.4%) 79 (100%)
Table 3 Expression of markers in low and high-grade
astrocytomas, p63 expression
p63 P value
Tumor Negative Positive Total
Low-Grade 16 (66.7%) 8 (33.3%) 24 (100%) P < 0.001
High-Grade 20 (25.3%) 59 (74.7%) 79 (100%)
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The MS-MLPA (methylation-specific multiplex ligation-
dependent probe amplification) Kit ME011 (MRC-Holland)
was used to detect aberrant methylation in MGMT gene
promoter region using probes that recognized sequences
containing a methylation-sensitive restriction site HhaI
[34]. All reactions were carried out as described by the
kit manufacturer using in each reaction 150 ng of tumor
DNA. PCR reaction products were separated by capillary
gel electrophoresis (ABI Prism 3100 Genetic Analyzer,
Applied Biosystems) and quantified using the Genemapper
software (Applied Biosystems). MS-MLPA processing
was performed using Coffalyser analysis tool as previously
described [34].
Fluorescence in situ hybridization (FISH)
Dual-probe FISH analysis was performed on TMA sections
using locus-specific probes for centromere 7/EGFR gene and
centromere 10/PTEN gene (Vysis, Dowerners Grove, IL).
FISH studies were carried out following well-established
methods as described before [35]. Specimens were con-
sidered to have an amplification of EFGR when more
than 20% of tumor cells exhibited an EGFR/CEP7 ratio >2
or inestimable tight clusters of signals of the locus probe;
and PTEN deletion was defined as more than 20% of tumor
cells containing one or no PTEN locus signal and the
presence of reference CEP signal.
Cell culture and immunoblot analysis
The glioblastoma cell lines A172, LN18 and LN229 were
obtained from the ATCC and were grown in DMEM with
10% fetal calf serum supplemented with glutamine and
antibiotics. Cell lysates and immunoblots were performed
as previously reported [26,27,31]. VRK2 was detected with
a rabbit polyclonal [28,29]; VRK1 with a rabbit polyclonal
[33]; EGFR (sc-3,Santa Cruz Biotechnology); ErbB2
(mAb 44E7, Cell Signaling); cyclin D1(sc-450,Santa Cruz
Biotechnology); β-actin (mAb AC-15,Sigma).Table 2 Expression of markers in low and high-grade
astrocytomas, VRK2 expression
VRK2 (cytoplasmic staining) P value
Tumor Negative Positive Total
Low-Grade 14 (58.3%) 10 (41.7%) 24 (100%) P = 0.021
High-Grade 25 (32.1%) 53 (67.9%) 78 (100%)Immunofluorescence and confocal microscopy
The subcellular localization of endogenous VRK1 and
VRK2 was determined in the indicated cells lines grown on
coverslips and stained with the corresponding antibodies as
previously reported [28,31,32]. Fluorescence images were
captured with a LEICA TCS SP5 DMI-6000B confocal
microscope (Leica) and were analyzed with LEICA LAS AF
(Leica) and ImageJ (NIH, http://rsb.info.nih.gov/ij) software.
Statistical analysis
Associations between molecular and clinicopathological
features were analyzed using either the Fisher’s exact test or
the chi-square contingency test. Survival models were used
to identify correlations between molecular, histopathology
and clinical parameters and survival data from the 105
astrocytoma patients. Overall survival was estimated from
the date of diagnosis until death or last follow-up, and those
patients lost during follow-up were censored. Survival times
were estimated by the Kaplan Meier method and compared
among patient subsets using the log-rank test. Cox pro-
portional hazards model was used to identify independent
prognostic factors in glioma patients. A prognostic index
was constructed with those significant variables that predict
survival using the Cox regression coefficients derived from
Cox model [36]. Patients were ranked according to their
risk score and divided into two groups using the median
risk score as cut-off. The results were reported following the
reporting recommendations for tumor marker prognostic
studies (REMARK) criteria [37]. Differences with a p-value
smaller than 0.05 were considered as statistically significant,
and all tests were two-sided. All statistical analyses were
performed using SPSS v.18.0 program (SPSS, Inc.).
Results
Expression of VRK1 and VRK2 serine-threonine kinases in
human astrocytomas and correlations with tumor grade
The expression of VRK1 and VRK2 proteins was deter-
mined in 105 astrocytomas. A representative stainingTable 4 Expression of markers in low and high-grade
astrocytomas, Ki-67 expression
ki-67 P value
Tumor 0-5% 5-15% >15% Total
Low-Grade 21 (91.3%) 2 (8.7%) 0 (0.0%) 23 (100%) P < 0.001
High-Grade 18 (28.6%) 24 (38.1%) 21 (33.3%) 63 (100%)
Table 5 Correlation of VRK1 with proliferation marker p63
p63
Tumor VRK1 (nuclear staining) Negative Positive Total P value
Low-Grade
Negative 13 (54.2%) 2 (8.3%)
24 (100%) 0.007
Positive 3 (12.5%) 6 (25.0%)
High-Grade
Negative 15 (19.0%) 21 (26.6%)
79 (100%) 0.002
Positive 5 (6.3%) 38 (48.1%)
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and VRK2 proteins, in low and high-grade astrocytoma
cases, are shown in Figure 1. VRK1 was mostly detected in
the nucleus (Figure 1) [17,33], and there is also a minor
VRK1 cytosolic subpopulation located in Golgi (not shown)
[18,38]. The main VRK1 nuclear subpopulation was higher
in high-grade tumors, including anaplastic astrocytomas
and glioblastomas, but did not reach significance (Table 1).
VRK2 is mostly a cytosolic protein (Figure 1) anchored
to the endoplasmic reticulum [28]. VRK2 protein level
and tumor grade presented a positive correlation, thus in
high-grade astrocytomas its level was significantly higher
than in low-grade astrocytomas (Table 2).
VRK protein correlations with proliferation markers p63
and ki67
Both VRK1 and VRK2 proteins have been associated
with the proliferation phenotype in carcinomas [15,26,27].
Therefore, we also determined the expression of p63
and ki67 proliferation markers as well as p53 expression
(Additional file 4: Figure S1), and they were analyzed with
respect to VRK1 and VRK2 protein levels. Considering
each marker individually, p63 and ki67 significantly cor-
related with high-grade astrocytomas, reflecting a higher
proliferative component in these tumors (Tables 3 and 4),
however, the correlation between p63 and ki67 was not
significant (data not shown), indicating that these two
proliferation markers might vary among tumors. VRK1
expression only correlated with p63 expression in both
low and high-grade astrocytomas, while VRK2 expression
correlated with ki67 levels only in high-grade astrocytomas
(Tables 5 and 6). However, p53 expression was not cor-
related with tumor grade or with VRK1 or VRK2 expres-
sion (data not shown).Table 6 Correlation of VRK2 with proliferation marker ki-67
Tumor VRK2 (cytoplasmic staining) 0-5%
Low-Grade
Negative 13 (56.6%)
Positive 8 (34.8%)
High-Grade
Negative 9 (14.5%)
Positive 8 (12.9%)Mutation profile of astrocytomas
To genetically characterize this astrocytoma series, we
determined several alterations in IDH1/2, p53, MGMT,
EGFR and PTEN genes that are known to be frequent in
astrocytomas [6].
The frequency of p53 mutations was significantly
higher in low-grade astrocytomas (12/24, 50.0%) than
in high-grade astrocytomas (17/73, 23.3%) (p = 0.013).
IDH1/2 mutations were also correlated with low-grade
astrocytomas (15/24, 62.5%), and are infrequent in high-
grade tumors (3/74, 4.1%) (p < 0.001). On the contrary,
loss of PTEN locus were more frequent in high-grade
astrocytomas (49/65, 75.4%) than in low-grade astrocy-
tomas (4/12, 33.3%) (p = 0.007), and EGFR amplification
was only detected in high-grade tumors (26/73, 35.6%)
(p = 0.002). Finally, MGMT promoter methylation status did
not show a differential pattern based on tumor grade, 62.5%
(15/24) of low-grade astrocytomas and 46.8% (36/77) of
high-grade astrocytomas showedMGMT hypermethylation.
However, we did not find any significant statistical as-
sociation between these common alterations in astro-
cytomas and VRK1 or VRK2 protein expression levels
(Additional file 5: Table S4).
High VRK2 protein expression correlated with improved
survival and is an independent marker of prognosis
A survival analysis was performed to investigate the
prognostic impact of these proteins in low and high-
grade astrocytomas outcome (Figure 2). VRK2 protein
expression was significantly associated with survival in
high-grade astrocytomas. Those patients with high VRK2
protein expression had a better median overall survival
(13.7 months vs. 10.2 months) (Table 7) (Figure 2A). Age
(≤60 years vs. >60 years) and treatment (radiotherapy pluski-67
5-15% >15% Total P value
1 (4.3%) 0 (0.0%)
23 (100%) 0.742
1 (4.3%) 0 (0.0%)
2 (3.2%) 5 (8.1%)
62 (100%) 0.005
22 (35.5%) 16 (25.8%)
n = 24
p = 0.222
Time (months)
Su
rv
iv
al
 P
ro
ba
bi
lit
y
Low-grade gliomas
1.0
0.8
0.6
0.4
0.2
0.0
1251007550250
High VRK2
Low VRK2
n = 74
p = 0.025
Su
rv
iv
al
 P
ro
ba
bi
lit
y
Time (months)
High-grade gliomas
1.0
0.8
0.6
0.4
0.2
0.0
1251007550250
High VRK2
Low VRK2
A B
C
Time (months)
Su
rv
iv
al
 P
ro
ba
bi
lit
y
1251007550250
1.0
0.8
0.6
0.4
0.2
0.0
Low-risk group
High-risk group
n = 74
p < 0.001
Figure 2 VRK2 and astrocytoma survival. Kaplan-Meier estimates of overall survival in (A) low-grade astrocytomas and (B) high-grade
astrocytomas according to VRK2 protein expression. (C). Kaplan-Meier estimates of overall survival for low-risk and high-risk groups, based on the
prognostic index combining VRK2 protein level, age and treatment (Table 6) in cases of high-grade astrocytomas.
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were also significantly associated with improved survival
in high-grade astrocytomas by univariate analysis (Table 7).
In addition, low-grade astrocytomas with high VRK2 pro-
tein levels also had better prognosis but this association
did not reach statistical significance probably due to the
lower number of cases in this group (Figure 2B).
Furthermore, multivariate Cox model revealed that VRK2
expression, age and treatment were statistically significant
independent predictors of high-grade astrocytoma survival
(Table 7). Next, we constructed a prognostic index based
on multivariate analysis for predicting patients’ survival
with the following prognostic index formula derived fromTable 7 VRK2 as independent marker in univariate and multi
Parameter HR (95
VRK2 expression 1.80 (1.0
Age (<60 vs. ≥ 60) 1.94 (1.1
Treatment (Chemo + RT vs. RT alone vs. no treatment) 1.96 (1.2
HR: hazard ratio. RT: Radiotherapy. Chemo: Chemotherapy.Cox coefficients: 0.744 × VRK2 expression + 0.585 × age +
0.697 × treatment. Patients were divided into low-risk
group and high-risk group according to their risk score
(Table 8). Thus, patients in the high-risk group had a
poor outcome compared to low-risk group of patients
(9.8 months vs. 15.7 months) (Figure 2C) (Table 8).
High VRK2 expression in astrocytoma cell lines restricts
cell growth
Next, it was determined if glioblastoma cells lines are
representative of main tumor and thus can be of use to
study glioblastoma signaling characteristics. For this aim
the expression and subcellular localization of VRK1 andvariate survival analysis in high-grade astrocytomas
Univariate analysis Multivariate analysis
% C.I.) P value HR (95% C.I.) P value
7 – 3.02) 0.025 2.10 (1.24 – 3.58) 0.006
5 – 3.26) 0.011 1.80 (1.06 – 3.05) 0.031
2 – 3.15) 0.003 2.01 (1.22 – 3.30) 0.006
Table 8 VRK2 as prognostic index in astrocytomas
Risk group No. patients % Hazard ratio(95% C.I.)
Median survival
(months) (95% C.I.) P value
Survival rate
1-year 2-year 3-year
Low-risk 28 (37.8%) 1 15.7 (12.3 – 19.0)
<0.001
67.9% 25.5% 21.3%
High-risk 46 (62.2%) 2.64 (1.53 – 4.55) 9.8 (7.9 – 11.8) 39.8% 7.0% 0.0%
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lines, A172, LN18 and LN229 by immunofluorescence
(Additional file 6: Figure S2), and the pattern detected
was similar to that observed in astrocytoma biopsies.
All cell lines express similar levels of VRK1 and VRK2,
but LN18 has a higher level of EGFR and higher EGFR/
VRK ratios (Figure 3A), as well as lower cyclin D1.
Two cell lines, A172 and LN229, have a higher level of
cyclin D1, suggesting that in relative terms there are
more cells in G1 phase of the cycle due to their slower
progression, a pattern that is inversely correlated with
the level of EGFR (Figure 3A). If this interpretation is
correct LN18 cells should grow faster than A172 or
LN229 cells. Next, it was determined if the growth rate
of these three astrocytoma cell lines was in accordance
with their EGFR/VRK2 ratio. The LN18 cell line had a
higher proliferation rate and a doubling-time of 19 hours
(Figure 3B). This cell line has a higher EGFR/VRK2 ratio
(Figure 3A) and lower levels cyclin D1 consistent with the
progression of cell cycle after serum readdition (Figure 3B).
The other cell lines had a doubling-time of 34 hours,
and their EGFR/VRK2 ratio was half of that in LN18
cells (Figure 3B).LN
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Figure 3 Protein expression in glioblastoma cell lines. VRK1, VRK2, EGF
cell lines (A). At the bottom the ratio of EGFR expression respect to VRK pr
astrocytoma cell lines (B). Cells were seeded in P60 dishes and were serum
was determined at different time points after serum readdition. To the righ
after serum readdition. The values are the mean of three independent expDiscussion
High-grade astrocytomas overexpress high VRK1 and
VRK2 RNA [39] and protein levels (this work). The
correlation of VRK1 with p63 expression and the cor-
relation of VRK2 with ki67 levels are very consistent
with the association of VRK1 and VRK2 with a pro-
liferation phenotype as it had been reported in head
and neck squamous cells carcinomas [15,26]. How-
ever, the lack of correlation between VRK1 or VRK2
with p53 levels could be due as a result of mutations
in p53 gene that inactivate the downregulation of VRK1
[18,24,25] that is mediated in the autophagic pathway
by DRAM [25].
In our series, low-grade astrocytomas are characterized
with p53 and IDH1/2 mutations, consistent with known
frequencies for this group [6]; whereas PTEN loss and
EGFR amplification that facilitate survival signaling by the
resulting constitutive activation of the PI3K pathway [40]
were more represented in high-grade astrocytomas [6].
However, none of these alterations were related to VRK1
or VRK2 expression in astrocytomas, suggesting that these
proteins could be involved in astrocytoma pathogenesis by
different mechanisms.rum
Time ( hours)
10 20 30 40 50 60 70
A172
LN18
LN229
***
***
***
R and cyclin D1 protein levels were determined in three glioblastoma
oteins expression in each cell line is shown. Growth rate of
deprived for 24 hours. At time 0, serum was added and cell number
t is shown the growth curve of each cell line at different time points
eriments and the standard deviations are shown. *** P < 0.001.
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http://www.biomedcentral.com/1472-6890/13/23Furthermore, survival analysis showed that high levels
of VRK2 were significantly associated with longer survival
in high-grade astrocytomas independently of age or
treatment of patients. This association of VRK2 ex-
pression to a better prognosis in malignant astrocyto-
mas is likely to be associated to the roles that VRK2
plays in the modulation of mitogenic, stress or apop-
tosis signaling [29-32]. High levels of VRK2 are known
to inhibit the mitogenic signal mediated by activation
of the RTK (receptor tyrosine kinase)-Ras-RAF-MEK
pathway. VRK2A retains the KSR1 scaffold protein in a
membrane-associated form bound to the endoplasmic
reticulum and downregulates Erk activation [31,32]. In
addition, high VRK2 levels also inhibit the cellular response
to stress induced by hypoxia [29] and by inflammatory
interleukins [30]. Thus, high VRK2 expression might
reduce the strength of the mitogenic signals and con-
tribute to a reduced growth rate as detected in the
astrocytoma cell line with higher VRK2 relative level.
In that way VRK2 might contribute to the tumor bio-
logical characteristics by modulation of neural cells to
growth factors. The combined role of these functions
might result in a tumor with a lower growth rate and
that is also more indolent. This is consistent with the
role of high VRK2 level in breast cancer, in which also
correlates with tumors having a better prognosis, those
that are estrogen and progesterone receptor positive and
ERBB2 negative [31,32].
In summary, in this work we have identified the potential
value of VRK2 expression as marker of a better prognosis
in astrocytomas. The identification of prognostic markers
in these lethal tumors is an important issue in order to
understand their pathogenesis and might provide basis
for the development of new therapeutic strategies.
Conclusion
High levels of VRK2 protein is an indicator of a better
prognosis in primary high-grade astrocytomas.Additional files
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